Noticias > Press Release: OWL Metabolomics to present data in the field of NASH diagnosis and therapeutic treatment at The Liver Meeting® 2021



Press Release: OWL Metabolomics to present data in the field of NASH diagnosis and therapeutic treatment at The Liver Meeting® 2021

This congress will bring together the top hepatologists and presents the most cutting-edge science in the field from 12th to 15th November.

OWL Metabolomics will participate in the event presenting 3 posters, which will display its scientific advances in the field of diagnosis and therapeutic treatment of non-alcoholic steatohepatitis (NASH).

Bilbao, 26th October 2021. The Liver Meeting® brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

The event, organised by the American Association for the Study of Liver Disease (AASLD), will be held in a digital format from Friday 12th November to Monday 15th November 2021.

In this edition, OWL Metabolomics will present its scientific contribution to the field in 3 different studies to help in the management of NAFLD. Pablo Ortiz, Scientific Director at OWL, explains “We present 3 metabolomic studies showing: a) the stratification of NAFLD patients in its major clinical relevant stages (simple steatosis, NASH or NASH + significant fibrosis), through OWLiver panel, b) a new way to present cardiovascular risk evaluation of saroglitazar through NMR lipoprotein profiling evolution after drug administration, and c) the identification of 3 different subtypes of NASH through metabolomics signature analysis and their association with different cardiovascular disease risk”.

Diagnostics advances in NASH

The poster “Diagnostic performance of metabolomic test to detect non-alcoholic steatohepatitis and significant fibrosis in patients at high risk of progressive fatty liver disease” (Abstract number 1593) focuses on the performance of non-invasive methods, including the serum metabolomic tests OWLiver DM2 and OWLiver F2+, for the diagnosis of NASH and significant fibrosis. In this study, 140 biopsy-proven NAFLD patients were recruited from 6 Spanish hospitals (Hospital Universitario Marqués De Valdecilla, Hospital Clínico Universitario De Valladolid, Hospital General Universitario Gregorio Marañón, Hospital Universitario Virgen Del Rocío, Hospital Universitario Puerta De Hierro, Hospital Universitario Ramón y Cajal). FIB-4, FibroScan and the metabolomics tests were performed. The diagnostic performance of FIB-4 in patients at high risk of progressive NASH was poor, and the sequential employment of FIB-4 and OWLiver panel provided an accurate, quick serum-based, easy to use screening tool in this high risk population. OWLiver F2+ was also compared to FibroScan, having both methods similar diagnostic performances to identify patients with fibrosis ≥2.

Cardiovascular risk evaluation in NASH

The second poster, “Saroglitazar is associated with improved arterial contour and cardiovascular risk in patients with NAFLD” (Abstract number 1732) assesses saroglitazar effect on complex lipoprotein parameters influencing cardiovascular risk (CVR) and its impact on CVR relative to the general population. Zydus, Biosfer and OWL collaborate in this study, in which an arterial contour (AC) silhouette, created with weighted 10 major CVR drivers, was employed to help visualize the global lipoprotein profile in relation to CVR. Results showed that 16 weeks of treatment with saroglitazar highest dose was associated with improved AC and reduced CVR in patients with NAFLD/NASH from Evidences IV study relative to the general population. AC shows to be a useful tool to provide a more global visual assessment of CVR in patients with NAFLD than traditional lipid profile parameters.

Subtyping NASH through serum metabolomics signature

The third poster, “Metabolic subtypes of non-alcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles” (Abstract number 1619) associates different subtypes of NAFLD patients with different cardiovascular disease (CVD) risk. This study was performed in collaboration with CIC bioGUNE, Cedars-Sinai Medical Center, Ciberehd, Washington University School of Medicine, Biodonostia Research Institute, Charles University, Medical University of Warsaw, Saarland University Medical Center, TNO, Alcalá University, Galmed, University of Valladolid, Hospital Universitario Marqués De Valdecilla, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Del Rocío, Pontificia Universidad Católica De Chile, University of Florida, University of Torino, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. Employing the serum of an international cohort of 1099 biopsy-proven NAFLD individuals, three NAFLD subtypes were identified, independent of histological disease severity or known genetic risk factors for NAFLD. One of these 3 subtypes phenocopied the metabolome of mice with impaired VLDL-TG secretion; while another one phenocopied the metabolome of a model with normal secretion and the third one showed an intermediate signature. These signatures align with different lipoprotein profile and different CVD risk and may account for the variation in hepatic vs. cardiovascular outcomes, offering novel, clinically relevant, risk stratification.

About OWL

OWL is a global metabolomics service provider to the pharma industry with a main focus supporting clinical trials in liver diseases and other prevalent human diseases as well as research in indications where metabolomics plays a key role including drug therapy monitoring and biomarker discovery.

Since its inception in 2002 the company has collaborated with numerous NASH pharmaceutical and biotechnology companies and research organizations around the world within the liver field thanks to the creation of its exclusive metabolomic analysis platform. In addition, it participates in the two international consortia (LITMUS) and (NIMBLE) created to find non-invasive and reliable systems to replace liver biopsy in the diagnosis and prognosis of NASH. For more information, please visit

For further information, contact:

Miriam Pérez
Business developer
+34 688 641 824

Descargar archivo

Volver a listado de noticias

Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - España
+34 94 431 85 40

A través de su web, OWL pretende contribuir a la divulgación de la ciencia y a la mejora de la salud y el bienestar de las personas. El carácter de la web es
meramente divulgativo y en ningún caso puede sustituir la relación médico-paciente. Ante cualquier duda, acuda a su centro médico o especialista.
Última actualización: 20/07/2022

Con la colaboración de: